An equivalent dosage of human umbilical cord-derived mesenchymal stem cell (HucMSC), adipose tissue-derived mesenchymal stem cell (ADSC), and SVF was orthotopically administered into a cyclophosphamide (CTX)-induced premature ovarian insufficiency (POI) mouse model. The therapeutic impacts were meticulously evaluated employing a suite of assays. The underlying mechanisms were investigated through RNA sequencing (RNA-seq) and mass spectrometry, offering insights into the cellular and molecular responses.